CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
7.80
0.13%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.23
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 7.81
Open* 7.6
1-Year Change* -48.92%
Day's Range* 7.6 - 7.85
52 wk Range 0.17-2.29
Average Volume (10 days) 1.21M
Average Volume (3 months) 23.44M
Market Cap 14.64M
P/E Ratio -100.00K
Shares Outstanding 73.21M
Revenue 8.40M
EPS -1.95
Dividend (Yield %) N/A
Beta 1.14
Next Earnings Date Nov 14, 2022

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 27, 2024 7.81 0.17 2.23% 7.64 7.89 7.64
Mar 26, 2024 7.83 0.12 1.56% 7.71 7.87 7.58
Mar 25, 2024 7.86 0.02 0.26% 7.84 7.93 7.84
Mar 22, 2024 7.87 0.04 0.51% 7.83 7.87 7.77
Mar 21, 2024 7.81 0.23 3.03% 7.58 7.94 7.58
Mar 20, 2024 7.76 0.10 1.31% 7.66 7.92 7.66
Mar 19, 2024 7.66 0.15 2.00% 7.51 7.67 7.51
Mar 18, 2024 7.66 0.19 2.54% 7.47 7.86 7.47
Mar 15, 2024 7.51 0.04 0.54% 7.47 7.64 7.47
Mar 14, 2024 7.48 -0.01 -0.13% 7.49 7.56 7.34
Mar 13, 2024 7.50 0.04 0.54% 7.46 7.61 7.38
Mar 12, 2024 7.53 0.06 0.80% 7.47 7.60 7.47
Mar 11, 2024 7.51 0.07 0.94% 7.44 7.78 7.39
Mar 8, 2024 7.36 0.10 1.38% 7.26 7.47 7.26
Mar 7, 2024 7.28 -0.03 -0.41% 7.31 7.46 7.26
Mar 6, 2024 7.33 -0.03 -0.41% 7.36 7.46 7.26
Mar 5, 2024 7.37 0.11 1.52% 7.26 7.48 7.26
Mar 4, 2024 7.49 0.22 3.03% 7.27 7.71 7.26
Mar 1, 2024 7.27 0.25 3.56% 7.02 7.36 6.99
Feb 29, 2024 7.05 -0.09 -1.26% 7.14 7.16 6.97

Kala Pharma Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Total revenue 11.24 6.362 6.074 0 0
Revenue 11.24 6.362 6.074 0 0
Total Operating Expense 145.569 102.593 94.298 65.111 39.875
Selling/General/Admin. Expenses, Total 105.061 81.068 65.015 35.431 10.867
Research & Development 38.132 18.352 27.275 29.29 29.008
Operating Income -134.329 -96.231 -88.224 -65.111 -39.875
Interest Income (Expense), Net Non-Operating -8.276 -8.096 -6.123 -1.627 -2.336
Net Income Before Taxes -142.605 -104.327 -94.347 -66.738 -42.211
Net Income After Taxes -142.605 -104.327 -94.347 -66.738 -42.211
Net Income Before Extra. Items -142.605 -104.327 -94.347 -66.738 -42.211
Net Income -142.605 -104.327 -94.347 -66.738 -42.211
Income Available to Common Excl. Extra. Items -142.605 -104.327 -94.347 -66.738 -42.211
Income Available to Common Incl. Extra. Items -142.605 -104.327 -94.347 -66.738 -42.211
Dilution Adjustment
Diluted Net Income -142.605 -104.327 -94.347 -66.738 -42.211
Diluted Weighted Average Shares 65.2028 52.3775 34.2098 26.7539 6.90324
Diluted EPS Excluding Extraordinary Items -2.1871 -1.99183 -2.7579 -2.49451 -6.11467
Dividends per Share - Common Stock Primary Issue 0
Diluted Normalized EPS -2.12446 -1.99183 -2.7579 -2.47994 -6.11467
Unusual Expense (Income) 4.084 0 0.39
Cost of Revenue, Total 4.097 3.173 2.008
Gross Profit 7.143 3.189 4.066
Other Operating Expenses, Total -5.805
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Total revenue 1.372 1.856 3.067 3.051 3.266
Revenue 1.372 1.856 3.067 3.051 3.266
Cost of Revenue, Total 0.775 1.418 0.908 1.016 0.755
Gross Profit 0.597 0.438 2.159 2.035 2.511
Total Operating Expense 32.286 47.36 29.138 37.491 31.58
Selling/General/Admin. Expenses, Total 26.982 24.027 25.349 27.986 27.699
Research & Development 4.466 29.031 2.881 3.094 3.126
Operating Income -30.914 -45.504 -26.071 -34.44 -28.314
Interest Income (Expense), Net Non-Operating -2.027 -2.064 -2.056 -2.058 -2.098
Net Income Before Taxes -32.941 -47.568 -28.127 -36.498 -30.412
Net Income After Taxes -32.941 -47.568 -28.127 -36.498 -30.412
Net Income Before Extra. Items -32.941 -47.568 -28.127 -36.498 -30.412
Net Income -32.941 -47.568 -28.127 -36.498 -30.412
Income Available to Common Excl. Extra. Items -32.941 -47.568 -28.127 -36.498 -30.412
Income Available to Common Incl. Extra. Items -32.941 -47.568 -28.127 -36.498 -30.412
Diluted Net Income -32.941 -47.568 -28.127 -36.498 -30.412
Diluted Weighted Average Shares 73.6408 69.5132 65.0505 64.5545 61.6559
Diluted EPS Excluding Extraordinary Items -0.44732 -0.6843 -0.43239 -0.56538 -0.49325
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.44732 -0.70316 -0.43239 -0.48181 -0.49325
Unusual Expense (Income) -1.311 0 5.395
Other Operating Expenses, Total 0.063 -5.805
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Total Current Assets 124.366 171.379 105.484 177.028 115.213
Cash and Short Term Investments 92.136 153.54 85.449 170.898 114.565
Cash 92.136 77.264 85.449 170.898 114.565
Prepaid Expenses 1.307 1.807 1.605 0.532 0.648
Other Current Assets, Total 4.829 0.949 0.684 0.477
Total Assets 139.427 221.606 154.323 220.966 116.546
Property/Plant/Equipment, Total - Net 4.021 31.019 32.479 31.732 1.199
Property/Plant/Equipment, Total - Gross 6.882 34.443 34.995 33.55
Accumulated Depreciation, Total -2.861 -3.424 -2.516 -1.818
Other Long Term Assets, Total 11.04 19.208 16.36 12.206 0.134
Total Current Liabilities 37.422 22.225 24.774 17.01 14.872
Accounts Payable 4.899 1.724 2.518 5.446 1.202
Accrued Expenses 21.697 20.501 22.256 11.564 7.003
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0 6.667
Total Liabilities 122.623 121.611 124.631 115.988 26.867
Total Long Term Debt 78.929 72.243 71.184 70.226 11.987
Long Term Debt 78.929 72.243 71.184 70.226 11.987
Other Liabilities, Total 6.272 27.143 28.673 28.752 0.008
Total Equity 16.804 99.995 29.692 104.978 89.679
Redeemable Preferred Stock 0 0
Common Stock 0.066 0.059 0.036 0.034 0.025
Additional Paid-In Capital 559.126 499.715 325.112 306.053 224.025
Retained Earnings (Accumulated Deficit) -542.388 -399.783 -295.456 -201.109 -134.371
Total Liabilities & Shareholders’ Equity 139.427 221.606 154.323 220.966 116.546
Total Common Shares Outstanding 65.5003 58.9154 36.0863 33.8631 24.5383
Total Receivables, Net 17.455 9.854 13.098 1.026
Total Inventory 8.639 5.229 4.648 4.095
Accounts Receivable - Trade, Net 15.345 9.604 11.563
Short Term Investments 0 76.276
Other Equity, Total 0 0.004
Other Current Liabilities, Total 10.826
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Total Current Assets 98.255 124.366 149.086 171.72 179.065
Cash and Short Term Investments 70.162 92.136 124.503 149.635 155.985
Cash 65.17 92.136 124.503 144.635 127.97
Short Term Investments 4.992 0 0 5 28.015
Total Receivables, Net 13.02 15.345 12.63 11.859 12.206
Accounts Receivable - Trade, Net 13.02 15.345 12.63 11.859 12.206
Total Inventory 10.531 8.639 7.708 8.046 8.241
Prepaid Expenses 4.542 5.293 4.245 2.18 2.633
Total Assets 111.574 139.427 193.814 215.464 229.827
Property/Plant/Equipment, Total - Net 4.089 4.021 30.481 31.369 31.584
Other Long Term Assets, Total 9.23 11.04 14.247 12.375 19.178
Total Current Liabilities 32.758 37.422 27.195 26.076 19.989
Accounts Payable 6.218 4.899 5.845 2.844 2.855
Accrued Expenses 21.864 21.697 21.35 23.232 17.134
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 116.858 122.623 132.345 131.194 120.035
Total Long Term Debt 79.361 78.929 78.491 78.055 72.521
Long Term Debt 79.361 78.929 78.491 78.055 72.521
Other Liabilities, Total 4.739 6.272 26.659 27.063 27.525
Total Equity -5.284 16.804 61.469 84.27 109.792
Common Stock 0.073 0.066 0.065 0.065 0.064
Additional Paid-In Capital 569.974 559.126 556.224 550.898 539.92
Retained Earnings (Accumulated Deficit) -575.329 -542.388 -494.82 -466.693 -430.195
Other Equity, Total -0.002 0 0 0 0.003
Total Liabilities & Shareholders’ Equity 111.574 139.427 193.814 215.464 229.827
Total Common Shares Outstanding 72.594 65.5003 65.0852 64.7702 63.8051
Other Current Assets, Total 2.953
Accumulated Depreciation, Total -2.861
Other Current Liabilities, Total 4.676 10.826
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Net income/Starting Line -142.605 -104.327 -94.347 -66.738 -42.211
Cash From Operating Activities -108.235 -90.694 -92.72 -54.121 -34.098
Cash From Operating Activities 0.975 0.912 0.843 0.352 0.287
Non-Cash Items 44.011 16.294 12.722 9.882 5.526
Cash Interest Paid 6.837 7.528 7.522 3.041 0.863
Changes in Working Capital -10.616 -3.573 -11.938 2.383 2.3
Cash From Investing Activities 70.803 -78.209 -1.335 -1.578 -0.48
Capital Expenditures -0.886 -1.942 -1.335 -1.578 -0.48
Cash From Financing Activities 42.554 160.628 8.982 124.104 103.696
Financing Cash Flow Items -2.25
Issuance (Retirement) of Stock, Net 42.817 160.66 9.012 71.296 97.057
Issuance (Retirement) of Debt, Net -0.263 -0.032 -0.03 52.808 8.889
Net Change in Cash 5.122 -8.275 -85.073 68.405 69.118
Other Investing Cash Flow Items, Total 71.689 -76.267
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Net income/Starting Line -32.941 -142.605 -95.037 -66.91 -30.412
Cash From Operating Activities -24.089 -108.235 -80.331 -54.248 -32.64
Cash From Operating Activities 0.157 0.975 0.763 0.504 0.248
Non-Cash Items 3.479 44.011 21.534 16.592 5.519
Cash Interest Paid 1.603 6.837 5.2 3.03 1.851
Changes in Working Capital 5.216 -10.616 -7.591 -4.434 -7.995
Cash From Investing Activities -5.073 70.803 75.426 70.705 48.031
Capital Expenditures -0.081 -0.886 -0.874 -0.545 -0.219
Other Investing Cash Flow Items, Total -4.992 71.689 76.3 71.25 48.25
Cash From Financing Activities 0.154 42.554 42.394 41.164 35.315
Issuance (Retirement) of Stock, Net 0.163 42.817 42.648 41.409 35.324
Issuance (Retirement) of Debt, Net -0.009 -0.263 -0.254 -0.245 -0.009
Net Change in Cash -29.008 5.122 37.489 57.621 50.706

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Kala Pharma Company profile

About Kala Pharmaceuticals Inc

Kala Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for diseases of the eye. The Company's product candidate includes EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% and INVELTYS (loteprednol etabonate ophthalmic suspension) 1%. Its EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25%, is a short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. INVELTYS (loteprednol etabonate ophthalmic suspension) 1%, is a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. The Company's AMPPLIFY technology uses selectively-sized nanoparticles that each have a proprietary coating. Its Preclinical Development Programs include rTKI Program for Retinal Diseases (KPI-285/KPI-286), SEGRM Program and Surface Targeted Steroid Program (KPI-333).

Financial summary

BRIEF: For the nine months ended 30 September 2021, Kala Pharmaceuticals Inc revenues increased from $4.1M to $9.4M. Net loss increased 30% to $95M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative - Balancing increase of 48% to $70.6M (expense), Stock-Based Compensation increase of 50% to $10.4M (expense).

Industry: Pharmaceuticals (NEC)

1167 Massachusetts Avenue
02476

Income Statement

  • Annual
  • Quarterly

News

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

Four reasons why Bitcoin is surging to record highs

Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.

10:18, 14 March 2024

China’s National People’s Congress: The markets have again been left wanting more

China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.

08:23, 8 March 2024
Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

13:14, 6 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

People also watch

ETH/USD

3,567.64 Price
+1.590% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

BTC/USD

70,819.35 Price
+2.860% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

US100

18,249.80 Price
-0.090% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

Gold

2,217.38 Price
+1.110% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 21:00 (UTC)
Spread 0.30

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading